

Reviewer 1

Currently, the sequential application of various therapies, including lenalidomide and protease inhibitor, has significantly prolonged the survival time of patients, but their prognosis is still far from ideal, and their heterogeneity and early recurrence rate are higher. Attention should be paid to find out a highly sensitive and reliable indicator for evaluating the prognosis of patients with the minimal residual disease detection technology development. There is little research about this field, and the ability of IL-32 to evaluate the prognosis of patients is not clear. In this study, the authors analyzed the expression of IL-32 in the bone marrow of multiple myeloma patients, and explored the impact of IL-32 on the prognosis of multiple myeloma patients. 1. A minor language editing is required for the manuscript. 2. Data in the tables are informative, but the tables requires an editing. 3. Too many references, and the discussion is long. I suggest the authors check and delete some very "old" references.

Answer: Dear reviewer, thanks for your comments and we have revised our manuscript according to your suggestion. 1. We read the manuscript again and revised the minor language polishing. 2. Tables have been revised. 3. The references list was revised, and the discussion has been shorten.

Reviewer 2

Well designed study with interesting results. I suggest to accept the manuscript after a minor language editing. No specific comments.

Answer: Thanks for your support and we have proofread the manuscript.